NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) R
Post# of 111
(Total Views: 214)
Posted On: 09/29/2022 4:01:45 PM
NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced its receipt of confirmation from the Nasdaq Stock Market LLC Hearing Panel that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). In addition, Nasdaq confirmed that Aditxt meets the stockholders’ equity requirement in Listing Rule 5550(b)(1) and all other applicable criteria for continued listing. Amro Albanna, co-founder, chairman and CEO of Aditxt, said that the company’s recent completion of a reverse stock split and closing of a $20 million public offering were key to the company’s successful Nasdaq compliance and continued progress within each of its programs toward commercialization. These programs include AditxtScore(TM), Adimune(TM) and Adivir(TM).
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced its receipt of confirmation from the Nasdaq Stock Market LLC Hearing Panel that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). In addition, Nasdaq confirmed that Aditxt meets the stockholders’ equity requirement in Listing Rule 5550(b)(1) and all other applicable criteria for continued listing. Amro Albanna, co-founder, chairman and CEO of Aditxt, said that the company’s recent completion of a reverse stock split and closing of a $20 million public offering were key to the company’s successful Nasdaq compliance and continued progress within each of its programs toward commercialization. These programs include AditxtScore(TM), Adimune(TM) and Adivir(TM).
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)ADiTx Therapeutics Inc. (ADTX) Stock Research Links
Scroll down for more posts ▼